Have molecularly targeted therapies improved overall survival in renal cell carcinoma?
- PMID: 21455732
- DOI: 10.1007/s11912-011-0167-y
Have molecularly targeted therapies improved overall survival in renal cell carcinoma?
Comment on
-
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.J Clin Oncol. 2010 May 1;28(13):2144-50. doi: 10.1200/JCO.2009.26.7849. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368553 Clinical Trial.
-
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.J Clin Oncol. 2010 May 1;28(13):2137-43. doi: 10.1200/JCO.2009.26.5561. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368558 Free PMC article. Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources